TCGA-A8-A07U-01A-11R-A034-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 25
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.720
- INTERFERON_GAMMA_RESPONSE+0.690
- ALLOGRAFT_REJECTION+0.620
- IL6_JAK_STAT3_SIGNALING+0.540
- INFLAMMATORY_RESPONSE+0.510
- COMPLEMENT+0.410
- G2M_CHECKPOINT+0.390
- IL2_STAT5_SIGNALING+0.380
- E2F_TARGETS+0.350
- MYC_TARGETS_V2+0.320
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.320
- DNA_REPAIR-0.270
- TGF_BETA_SIGNALING-0.270
- ESTROGEN_RESPONSE_LATE-0.210
- OXIDATIVE_PHOSPHORYLATION-0.130
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.110
- PROTEIN_SECRETION-0.110
- PEROXISOME-0.100
- P53_PATHWAY-0.090
- PANCREAS_BETA_CELLS-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_16_0031_E2_S98 | — | C | 0.912 |
| 2 | TCGA-AR-A1AT-01A-11R-A12P-07 | — | C | 0.902 |
| 3 | TCGA-AR-A1AJ-01A-21R-A12P-07 | — | D | 0.895 |
| 4 | 20050099.TNBC | — | D | 0.890 |
| 5 | TCGA-BH-A0BG-01A-11R-A115-07 | — | E | 0.883 |
| 6 | TCGA-E9-A3QA-01A-61R-A22K-07 | — | D | 0.877 |
| 7 | 20080189.TNBC | — | E | 0.875 |
| 8 | SRR27320692 | — | — | 0.869 |
| 9 | SRR975600 | — | — | 0.867 |
| 10 | MNG766 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.720 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.690 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.620 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |